|1.||Curtis, Sean P: 18 articles (01/2013 - 05/2002)|
|2.||Smugar, Steven S: 11 articles (12/2012 - 07/2007)|
|3.||Peloso, Paul M: 10 articles (01/2015 - 12/2010)|
|4.||Gammaitoni, Arnold: 9 articles (01/2015 - 12/2010)|
|5.||Wang, Hongwei: 9 articles (01/2015 - 04/2009)|
|6.||Moore, R Andrew: 9 articles (01/2015 - 01/2008)|
|7.||Laine, Loren: 9 articles (12/2012 - 08/2006)|
|8.||Cannon, Christopher P: 8 articles (12/2012 - 08/2006)|
|9.||Kaur, Amarjot: 8 articles (12/2012 - 11/2006)|
|10.||Reicin, Alise S: 8 articles (11/2006 - 01/2004)|
08/01/2003 - "Etoricoxib provided significant improvement from baseline versus placebo in pain intensity (4 weeks: 12.9 mm and 10.3 mm for 60-mg and 90-mg doses, P <.001 for each; 12 weeks: 10.5 mm and 7.5 mm for 60-mg and 90-mg doses, P =.001 and.018, respectively). "
01/01/2012 - "We pooled data from 2 placebo-controlled studies of etoricoxib in CLBP to evaluate 5 response criteria: 30% pain intensity (PI) reduction; 50% PI reduction; 20 mm absolute reduction (100 mm PI visual analog scale); patient global assessment of response to therapy (PGART); and the composite criteria of 30% reduction in PI+30% improvement in PGART of disease status+no worsening in function. "
06/01/2012 - "Etoricoxib, a selective Cox-2 inhibitor has been found to be effective in the management of acute pain. "
01/01/2002 - "Single-dose etoricoxib relieved pain in patients with postoperative dental pain in two studies. "
01/01/2015 - "They experienced flare upon NSAID withdrawal and demonstrated dose-dependent pain improvement with etoricoxib. "
01/01/2002 - "To evaluate the efficacy of 12 weeks of treatment with etoricoxib, a selective COX-2 inhibitor, in patients with osteoarthritis (OA) of the knee or hip. "
01/01/2008 - "Information was sought from a dose-response trial over 6 weeks in osteoarthritis using placebo and using etoricoxib at 5, 10, 30 and 60 mg daily. "
01/01/2005 - "The aim of this study was to evaluate the long-term efficacy and tolerability of etoricoxib, a COX-2 selective inhibitor, in osteoarthritis (OA) patients. "
01/01/2005 - "Etoricoxib in the treatment of osteoarthritis over 52-weeks: a double-blind, active-comparator controlled trial [NCT00242489]."
09/01/2002 - "To evaluate the clinical efficacy and tolerability of etoricoxib in the treatment of osteoarthritis (OA) of the knee and define the clinically active dose range for further clinical trials. "
01/01/2002 - "In patients with rheumatoid arthritis, improvements in tender and swollen joint counts and patient and investigator global assessment of disease activity were significantly greater in etoricoxib than in placebo recipients in two studies. "
10/01/2011 - "Further assessment of the clinically effective dose range of etoricoxib: a randomized, double-blinded, placebo-controlled trial in rheumatoid arthritis."
10/01/2011 - "To further assess the clinically active dose range of etoricoxib, a COX-2 selective inhibitor, in rheumatoid arthritis (RA). "
08/01/2002 - "A randomized, controlled, clinical trial of etoricoxib in the treatment of rheumatoid arthritis."
05/22/2002 - "Etoricoxib is a highly selective COX-2 inhibitor which was evaluated for the treatment of rheumatoid arthritis (RA). "
01/01/2014 - "Randomised, double-blind, placebo-controlled clinical trials of single dose, oral etoricoxib for acute postoperative pain in adults. "
12/01/2012 - "Evaluation of a single preoperative dose of etoricoxib for postoperative pain relief in therapeutic knee arthroscopy: a randomized trial."
01/01/2012 - "Randomised, double-blind, placebo-controlled clinical trials of single dose, oral etoricoxib for acute postoperative pain in adults. "
01/01/2009 - "Randomised, double-blind, placebo-controlled clinical trials of single dose, oral etoricoxib for acute postoperative pain in adults. "
01/01/2014 - "Single dose oral etoricoxib for acute postoperative pain in adults."
04/01/2005 - "Evaluation of the efficacy of etoricoxib in ankylosing spondylitis: results of a fifty-two-week, randomized, controlled study."
01/01/2015 - "To study the clinical and laboratory efficiency and safety of different etoricoxib (ET) regimens in patients with axial spondyloarthritis (axSpA), including ankylosing spondylitis. "
01/01/2015 - "[Efficiency and safety of different etoricoxib regimens in patients with axial spondyloarthritis, including ankylosing spondylitis]."
12/01/2012 - "Whether etoricoxib will also become a mainstay in the prevention of structural damage in ankylosing spondylitis is not yet clear."
12/01/2012 - "Literature searches were performed in PubMed, Web of Science, and the Cochrane library based on the terms "etoricoxib" and "ankylosing spondylitis" or "spondyloarthritis" as well as "safety" and "side-effects." Etoricoxib is useful in the first-line management of ankylosing spondylitis patients. "
|1.||Diclofenac (SR 38)
|5.||Cyclooxygenase 2 Inhibitors (COX-2 Inhibitors)
|6.||Non-Steroidal Anti-Inflammatory Agents (NSAIDs)
|9.||Prostaglandin-Endoperoxide Synthases (Cyclooxygenase)